Cervical cancer is the fourth most common cancer in women worldwide, with a global
incidence of 604,127 and an annual death rate of 341,831 in 2020. Patients with recurrent …

Cervical cancer is the leading gynecologic health problem which is considered as the 4th
most widespread tumour in women. The prevalence of this fatal ailment is emerging …

Summary Background On Aug 14, 2014, the US Food and Drug Administration approved the
antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis …

Background Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator
of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF …

Despite the introduction of screening and, latterly, vaccination programs in the developed
world, globally cervical cancer remains a significant health problem. For those diagnosed …

Objective This multicenter, open-label, phase II study aimed to evaluate the efficacy and
safety of paclitaxel–carboplatin, bevacizumab, and bevacizumab-based maintenance …

Cervical cancer is the second most common cause of cancer death in women worldwide
and the development of new diagnosis, prognostic, and treatment strategies merits special …

Abstract Since 1970, the Gynecologic Oncology Group (GOG) has been at the forefront of
evaluating and helping to implement ground breaking and paradigm changing research in …

When cervical cancer is beyond curative treatment with surgery or radiation therapy, the
prognosis is poor and palliation is the primary objective. Early prospective studies identified …

Objective Adding bevacizumab to cisplatin–paclitaxel for advanced cervical cancer
significantly improves overall and progression-free survival. We evaluated bevacizumab …